Aurobindo Pharma arm buys Khandelwal Lab's non-oncology ops for INR 3.3 bln
This story was originally published at 18:49 IST on 1 January 2026
Register to read our real-time news.Informist, Thursday, Jan. 1, 2026
--Aurobindo Pharma arm buys Khandelwal Lab's non-oncology ops for INR 3.3 bln
HYDERABAD – Aurobindo Pharma Ltd.'s board on Thursday approved the acquisition of the non-oncology prescription formulations business of Khandelwal Laboratories Pvt. Ltd. through its wholly owned subsidiary Auro Pharma Ltd. for a cash consideration of INR 3.3 billion. The acquisition is limited to only specific businesses and not shares or any control over Khandelwal Laboratories, Aurobindo Pharma said in an exchange filing. The acquisition is effective from Thursday, the company said.
The acquisition will help the company expand its prescription business in the domestic market, the company said. The acquisition includes 23 brands and 9 pipeline products covering anti-infective and pain management therapies. The acquired business has around 470 field force and has more than 1,600 stockists and distribution-related infrastructure. The acquired business generated INR 1.13 billion of revenue in 2024-25 (Apr-Mar), Aurobindo Pharma said.
In 2022, Aurobindo Pharma announced its foray into the domestic formulations business, with an aim to achieve INR-10-billion sales in three years. The company reported INR 2.5 billion sales for FY25 in India formulation business. In 2022, the company acquired the domestic formulations business of Veritaz Healthcare and GLS Pharma.
Aurobindo Pharma reported consolidated net profit of INR 8.48 billion for the September quarter on revenue of INR 82.86 billion. On Thursday, shares of the company ended 0.9% higher at INR 1,193 on the National Stock Exchange. End
Reported by Narayana Krishna
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
